A Trial to learn about the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Immune Thrombocytopenia

Recruiting
99 years or below
All
Phase N/A
20 participants needed
1 Location

Brief description of study

To evaluate the long-term safety and tolerability of mezagitamab in participants 18 years of age with chronic primary ITP.

To evaluate the long-term efficacy of mezagitamab in participants 18 years of age with chronic primary ITP. Occurrence of TEAEs and serious TEAEs. Occurrence of TEAEs leading to permanent withdrawal of mezagitamab.

TEAEs means treatment-emergent adverse event Duration of platelet response, measured by the cumulative number of weeks on which platelet count was 30,000/L throughout the trial.

The cumulative number of weeks on which platelet count was 50,000/L throughout the trial.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 26 Nov 2025. Study ID: 25-1889

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center